Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study

Bardur Sigurgeirssona Department of Dermatology, Faculty of Medicine, University of Iceland, Reykjavik, IcelandCorrespondence[email protected]

https://orcid.org/0000-0002-9733-9742 View further author information

Knut Schäkelb Department of Dermatology, Heidelberg University Hospital, Heidelberg and Interdisciplinary Center of Chronic Inflammatory Diseases, Heidelberg, GermanyView further author information

Chih-Ho Hongc Dr. Chih-Ho Hong Medical Inc., Surrey, Canada;d Probity Medical Research, Waterloo, Canada;e Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada

https://orcid.org/0000-0001-9963-8319 View further author information

Isaak Effendyf Department of Dermatology, Municipal Hospital of Bielefeld, Bielefeld, Germany

https://orcid.org/0000-0002-8293-6616 View further author information

Waldemar Placekg Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Waria and Mazury Olsztyn, Olsztyn, PolandView further author information

Phoebe Richh Department of Dermatology, Oregon Health and Science University, Portland, OR, USAView further author information

Deborah Keefei Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information

Gerard Bruinj Novartis Institutes for Biomedical Research, Basel, SwitzerlandView further author information

Pascal Charefk Novartis Pharma AG, Basel, SwitzerlandView further author information

Rong Ful Novartis Institute for Biomedical Research, Shanghai, ChinaView further author information

Isabelle Hampelek Novartis Pharma AG, Basel, SwitzerlandView further author information

Manmath Patekark Novartis Pharma AG, Basel, SwitzerlandView further author information

show all

Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study

Citations (3)

Read on this site (3)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date